Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
Microbiotica said the cash will support advancing its potential ulcerative colitis treatment into a phase two trial. Its initial study showed “statistically significant improvements,” according to the supplied report.
IP Group said portfolio company Microbiotica closed a £36m financing, in which IP Group invested £4m. Microbiotica is a clinical-stage biopharmaceutical company developing orally dosed precision microbiome medicines.
For best results when printing this announcement, please click on link below: RNS Number: 2049Z IP Group PLC 16 October 2026 FOR RELEASE ON 16 October 2026 Portfolio company Microbiotica raises £36m in Series C financing to advance pipeline into Phase 2 clinical development IP Group plc ("IP Group" or the "Group") (LSE